LEVALBUTEROL HYDROCHLORIDE solution

País: Estados Unidos

Idioma: inglés

Fuente: NLM (National Library of Medicine)

Cómpralo ahora

Ficha técnica Ficha técnica (SPC)
12-05-2018

Ingredientes activos:

LEVALBUTEROL HYDROCHLORIDE (UNII: WDQ1526QJM) (LEVALBUTEROL - UNII:EDN2NBH5SS)

Disponible desde:

Cardinal Health

Designación común internacional (DCI):

LEVALBUTEROL HYDROCHLORIDE

Composición:

LEVALBUTEROL 1.25 mg in 0.5 mL

tipo de receta:

PRESCRIPTION DRUG

Estado de Autorización:

Abbreviated New Drug Application

Ficha técnica

                                LEVALBUTEROL HYDROCHLORIDE- LEVALBUTEROL HYDROCHLORIDE SOLUTION
CARDINAL HEALTH
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LEVALBUTEROL INHALATION SOLUTION
(CONCENTRATE) SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION
FOR LEVALBUTEROL INHALATION
SOLUTION (CONCENTRATE).
LEVALBUTEROL INHALATION SOLUTION, USP (CONCENTRATE) FOR INHALATION USE
INITIAL U.S. APPROVAL: 1999
INDICATIONS AND USAGE
Levalbuterol inhalation solution, USP (concentrate) is a beta
-adrenergic agonist indicated for:
•
DOSAGE AND ADMINISTRATION
•
•
•
•
•
DOSAGE FORMS AND STRENGTHS
Inhalation Solution Concentrate (unit-dose vial for nebulization):
1.25 mg/0.5 mL. Dilute before use. (3)
CONTRAINDICATIONS
•
WARNINGS AND PRECAUTIONS
•
•
•
•
•
•
•
ADVERSE REACTIONS
Most common adverse reactions are: palpitations, chest pain,
tachycardia, headache, dizziness, tremor and nervousness.
(6)
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT MYLAN PHARMACEUTICALS
INC. AT 1-877-446-3679 (1-877-
4-INFO-RX) OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
DRUG INTERACTIONS
•
•
•
•
2
Treatment or prevention of bronchospasm in adults, adolescents, and
children 6 years of age and older with
reversible obstructive airway disease. (1)
FOR ORAL INHALATION ONLY (2)
Dilute levalbuterol inhalation solution (concentrate) with sterile
normal saline before administration by nebulization.
_Children 6 to 11 Years Old: _0.31 mg administered 3 times a day, by
nebulization. Routine dosing should not exceed
0.63 mg 3 times a day. (2)
_Adults and Adolescents _≥ _12 Years Old: _0.63 mg administered 3
times a day, every 6 to 8 hours, by nebulization. The
maximum recommended dose is 1.25 mg 3 times a day. (2)
For use with a standard jet nebulizer (with a face mask or mouthpiece)
connected to an air compressor. (2)
Hypersensitivity to levalbuterol or racemic albuterol. (4)
Life-threatening paradoxical bronchospasm may occur. Discontinue
levalbuterol inhalation solution 
                                
                                Leer el documento completo
                                
                            

Buscar alertas relacionadas con este producto